Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped After a careful review of the currently available treatments worldwide for patients with ATTR-polyneuropathy, Eidos has made the decision to halt the current study design.

Conditions

Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy

Interventions

DRUG: AG10
DRUG: Placebo

Sponsor

Eidos Therapeutics, a BridgeBio company